CHIMERIC ANTIGEN RECEPTOR SPACERS
Summary
The USPTO published Lyell Immunopharma's patent application US20260098075A1 for chimeric antigen receptors (CARs) incorporating immunoglobulin-derived spacers, such as hinge or loop regions, designed to enhance cytokine release compared to CARs with non-Ig-derived spacers. The spacers may be derived from human immunoglobulins (IgAQ1, IgA2, IgD, IgE, IgG1-4, IgM) or non-human sources (e.g., mouse IgG2A), and may be configured as modular constructs combining multiple Ig hinges or fragments thereof. Filed September 8, 2025.
What changed
The USPTO published Lyell Immunopharma's patent application for chimeric antigen receptors (CARs) incorporating immunoglobulin-derived spacers, such as hinge or loop regions from various immunoglobulin isotypes, designed to improve cytokine release properties compared to conventional spacers. The application covers CAR-expressing cells and methods of treating diseases, particularly cancer.
Affected parties in the biotechnology and pharmaceutical sectors should monitor this patent application and assess whether licensing may be necessary for developing similar CAR-based therapeutics. While the publication does not grant enforceable patent rights, it establishes the scope of claimed subject matter that may affect freedom-to-operate analyses for competing CAR-T and cell therapy programs.
What to do next
- Monitor USPTO prosecution status for patent application US20260098075A1
- Evaluate potential licensing implications for CAR-based therapeutic approaches
Archived snapshot
Apr 13, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
CHIMERIC ANTIGEN RECEPTOR SPACERS
Application US20260098075A1 Kind: A1 Apr 09, 2026
Assignee
Lyell Immunopharma, Inc.
Inventors
Marc Joseph LAJOIE, Brian Douglas WEITZNER, Scott Edward BOYKEN, Spencer PARK, Yun SONG
Abstract
The present disclosure related to chimeric antigen receptors (CARs) comprising immunoglobulin (Ig) derived spacers, e.g., hinge or loop regions, fragments thereof, or combinations thereof. Ig derived spacer confers improved properties to the CARs, e.g., increased cytokine release with respect the CARs with spacers not derived from hinge regions and fragments thereof, loop regions from constant domains and fragments thereof, and combinations thereof. Also provided are cells expressing CARs comprising Ig derived spacers regions and methods to use the CARs to treat diseases or disorders, e.g., cancer. Some of the disclosed Ig derived spacers are fragments from, e.g., IgAQ1, IgA2, IgD, IgE, IgG1, IgG2, IgG3, IgG4, or IgM. In some aspects, the disclosed Ig derived spacers are derived from non-human immunoglobulins, e.g., mouse immunoglobulins such IgG2A. Other Ig derived spacer disclosed are modular constructs comprising several concatenated Ig hinges or fragments thereof.
CPC Classifications
C07K 14/7051 A61K 40/11 A61K 40/31 A61K 40/4205 A61K 40/421 A61K 40/4211 A61P 35/00 C07K 7/06 C07K 16/30 C12N 5/0636 A61K 38/00 A61K 2039/505 C07K 2317/53 C07K 2319/03
Filing Date
2025-09-08
Application No.
19322325
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.